Q2 2024

Filed Apr 16, 2024 · 10-Q · 47 days after period end · 0001683168-24-002440

Q2 2024 · 10-Q

Revenue

$40.64K

— vs Q2 2023

Net Income

-$325.46K

N/M vs Q2 2023

EPS Diluted

-$0.01

N/M vs Q2 2023

Gross Profit$34,417—

Operating Income

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	$40.64K	$0.00	—	$0.00
Net Income	-$325.46K	-$2.62M	-$1.24M	-$534.76K
EPS Diluted	-$0.01	-$1.33	-$1.01	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR